Epilepsy Clinical Trial
— EPILITTOfficial title:
Clinical Evaluation of Interstitial Laser Thermal Therapy Under Continuous MRI Monitoring as a Minimally Invasive Treatment of Patients With Medically Unbalanced Partial Epilepsy
Laser Induced Interstitial Thermal Therapy (LITT) is a "minimally invasive" procedure that uses the heat generated by a laser light (65°) to destroy brain lesions by coagulation leading to lesion necrosis under real-time MRI monitoring. The laser optical fiber is implanted into the lesion using stereotaxy. This technique, which can be performed under local anesthesia and on an outpatient basis, proved its efficacy and safety in the treatment of brain metastases for the first time in the world in 2006 (A. Carpentier et al, 2008, 2011). Since then, more than 5,000 patients have been treated in the USA, including for epileptogenic lesions (FDA device and CE cleared). Our goal is to evaluate LITT on lesions with drug-resistant epilepsy for which surgical resection is impossible. No therapeutic trial evaluating LITT in this indication has been performed to date. It is therefore necessary to study its feasibility and tolerance.
Status | Recruiting |
Enrollment | 13 |
Est. completion date | August 15, 2024 |
Est. primary completion date | September 15, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Age =18 years and < 80 years 2. Patient with a medically unbalanced partial epilepsy 3. Patient with a lesional image(s) in morphological MRI responsible for epilepsy based on clinical and electrophysiological assessment, +/- PET +/- SPECT +/- MEG +/- sEEG 4. Patients for whom scheduled neurosurgical treatment with craniotomy appears difficult: Deep lesions, eloquent region lesions, patient reluctance to perform surgery. 5. Endorsement of the Multidisciplinary Meeting of Neuro-epileptology 6. Patient affiliated with a social security scheme 7. Patient who has signed prior, free and informed consent Exclusion Criteria: 1. Pharmacosensitive epilepsy 2. Patient with poor adherence to medication, or with psychological disorders 3. Patients under legal protection 4. Patient with a contraindication to MRI (metal shards, known allergy to gadolinium, etc.) 5. Anticoagulant and antiplatelet therapy underway, cannot be stopped. 6. Severe and unbalanced psychiatric disorders 7. Pregnant women. Women of childbearing age should use oral contraception throughout the study. 8. Allergy to local anaesthetics / general anaesthesia |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Pitié Salpêtrière | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris | Medtronic |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Frequency of post-surgical complication of grade greater or equal to 2 according to Mathon and al classification | To assess the safety and feasibility of laser-induced thermocoagulation of intracerebral lesions responsible for drug-resistant epilepsy. | Day 30 post-operative | |
Secondary | Seizure freedom evaluated with Engel classification | Evaluate the clinical epileptic efficacy of treatment based by the ILAE and Engel classifications. | Post surgery : Month 1, Month 3, Month 6, Month 12 | |
Secondary | Seizure freedom evaluated with ILAE (International League Against Epilepsy) classification | Evaluate the clinical epileptic efficacy of treatment based by the ILAE and Engel classifications. | Post surgery : Month 1, Month 3, Month 6, Month 12 | |
Secondary | Number of seizure per patient | Evaluate the frequency of seizure | Post surgery : Month 1, Month 3, Month 6, Month 12 | |
Secondary | Number of patient with at least one seizure with complex partial seizure | Evaluate the intensity of seizure after treatment. | Post surgery : Month 1, Month 3, Month 6, Month 12 | |
Secondary | Number of patient at least one modification of anti-epileptic treatment | Evaluation of clinical efficacy of treatment | Post surgery : Month 1, Month 3, Month 6, Month 12 | |
Secondary | Mean change of quantification of the number of interictal peaks over 30 minutes evaluated at surface EEG compared to the pre surgery surface EEG | Electrophysiological epileptic efficacy | Post surgery : Month 3, Month 6, Month 12 | |
Secondary | Mean change neuropsychological scores | Evaluate the effect on cognition by a postoperative neuropsychological evaluation, compared with the pre-treatment neuropsychological evaluation.The neuro-psychological test will be selected according to the location of the lesion/focus | Post surgery : Month 12 | |
Secondary | Mean change in Quality of Life in Epilepsy (QOLIE-31) scores | Evaluate the effect on quality of life by comparing the preoperative assessment with the postoperative assessments. | Post surgery : Month 6, Month 12 | |
Secondary | Incidence of adverse events | Evaluate the clinical tolerance of the procedure. | Day of surgery, Day 2, Day 7, Day 30 post-operative | |
Secondary | Mean consumption of anti-epileptic drugs and epilepsy-related care | To assess the medico-economic impact of the treatment | Post surgery : Month 12 | |
Secondary | Mean of major and minor axis measurements evaluated by measuring post-treatment morphological MRI images corresponding to induced necrosis in T1 gadolinium SPGR MRI | Evaluate the radiological epileptic efficacy of treatment | Month 1, Month 3, Month 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04595513 -
Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants
|
Phase 1/Phase 2 | |
Completed |
NCT02909387 -
Adapting Project UPLIFT for Blacks in Georgia
|
N/A | |
Completed |
NCT05552924 -
Self Acupressure on Fatigue and Sleep Quality in Epilepsy Patients
|
N/A | |
Terminated |
NCT01668654 -
Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS
|
Phase 3 | |
Not yet recruiting |
NCT05068323 -
Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients
|
N/A | |
Completed |
NCT03994718 -
Creative Arts II Study
|
N/A | |
Recruiting |
NCT04076449 -
Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
|
||
Completed |
NCT00782249 -
Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy
|
N/A | |
Completed |
NCT03683381 -
App-based Intervention for Treating Insomnia Among Patients With Epilepsy
|
N/A | |
Recruiting |
NCT05101161 -
Neurofeedback Using Implanted Deep Brain Stimulation Electrodes
|
N/A | |
Active, not recruiting |
NCT06034353 -
Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients
|
N/A | |
Recruiting |
NCT05769933 -
Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
|
||
Not yet recruiting |
NCT06408428 -
Glioma Intraoperative MicroElectroCorticoGraphy
|
N/A | |
Not yet recruiting |
NCT05559060 -
Comorbidities of Epilepsy(Cognitive and Psychiatric Dysfunction)
|
||
Completed |
NCT02646631 -
Behavioral and Educational Tools to Improve Epilepsy Care
|
N/A | |
Completed |
NCT02952456 -
Phenomenological Approach of Epilepsy in Patients With Epilepsy
|
||
Completed |
NCT02977208 -
Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use
|
Phase 4 | |
Recruiting |
NCT02539134 -
TAK-935 Multiple Rising Dose Study in Healthy Participants
|
Phase 1 | |
Completed |
NCT02491073 -
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
|
N/A | |
Terminated |
NCT02757547 -
Transcranial Magnetic Stimulation for Epilepsy
|
N/A |